Day One - Early Biomarker Development

Biomarkers are playing increasingly critical roles in the development of new drugs. As companies strive to improve biomarker strategy, successes are increasingly showing the utility of bioanalytical platforms, innovative technology applications and implementing biomarker strategy early.

With insights delivered by Jounce Therapeutics, Sanofi, AstraZeneca and more, join fellow thought leaders in addressing:

  • R&D informatics to help you uncover novel biomarker insights and inform decision making
  • How we can collaborate more effectively across the industry for successful pipeline progression from an early stage
  • Innovative technologies and diagnostics to help you analyse datasets and deepen understanding into your pipeline candidates
  • Female advocacy in the workplace and diversity in workforces to build inclusive and supportive teams in the Women & Diversity in Precision Medicine panel discussion

And much more!

Key Speakers Include:

Darrell Borger

Associate Director, Translational Oncology, ODDU

Takeda

Robert Pomponio

Global Scientific Advisor, Biomarkers & Clinical Bioanalysis TMED

Sanofi

Beth Trehu

Chief Medical Officer

Jounce Therapeutics

Day One

TUESDAY SEPTEMBER 29, 2020
10.00AM – 5.20PM EDT | 7.00AM – 2.20PM PDT

10.00 | 7.00 Speed Networking

Synopsis

Grab a quick coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

10.50 | 7.50 Chair’s Opening Remarks

11.00 | 8.00 Keynote Presentation: Identification of a Predictive Biomarker for an Immune Agonist; Lessons Learned from Vopratelimab

  • Beth Trehu Chief Medical Officer, Jounce Therapeutics

11.20 | 8.20 Purpose Driven Approach to Biomarker Strategy & Planning: Hint… It Begins Early & Evolves with the Program

  • Robert Pomponio Global Scientific Advisor, Biomarkers & Clinical Bioanalysis TMED, Sanofi

11.40 | 8.40 Panel Discussion: Conversations Between Pharma and Diagnostic Providers

  • Mark Roberts Senior Director, Diagnostics Development, Covance
  • Beth Trehu Chief Medical Officer, Jounce Therapeutics
  • Robert Pomponio Global Scientific Advisor, Biomarkers & Clinical Bioanalysis TMED, Sanofi

Synopsis

• How is technology development in pharmaceutical teams affecting diagnostic partnerships and early
drug-Dx collaboration for effective biomarker strategy?
• Are there ways in which each team throughout the industry can work more effectively together?

12.20 9.20 Enabling the Expansive Interrogation of a Tumor & Its Microenvironment from a Single Sample for Translational Research and Precision Medicine

  • Dawn McHugh Sr. Director, Strategic Business Development, Personalis
  • Kedar Hastak Sr. Field Applications Scientist, Personalis

12.40 9.40 Live Q&A

  • Kedar Hastak Sr. Field Applications Scientist, Personalis
  • Dawn McHugh Sr. Director, Strategic Business Development, Personalis

Women & Diversity in Precision Medicine

12.50 | 9.50 Panel Discussion

  • Elizabeth O’Day CEO & Founder, Olaris Therapeutics
  • Maria Orr Head, Precision Medicine, Biopharmaceuticals, AstraZeneca
  • Nina Green Vice President and General Manager, Companion Diagnostics, Agilent Technologies

Synopsis

  • Understanding the importance of female advocacy in the workplace
  • Adopting a female support system
  • Entering a post-COVID world: Building diverse teams and maximizing business creativity
  • Recognising the female leads in the pandemic response
  • Exploring HR metrics and laws surrounding salary renegotiation
  • Actioning changes: How the entire community can make valuable differences to ensure an inclusive, supportive workplace for the future of precision medicine

1.20 | 10.20 Speed Networking

Synopsis

Grab a bite to eat from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!

Applications of Technologies & Diagnostic Tests

1.35 | 10.35 Opening remarks

  • Colin Hill VP/GM Clinical Diagnostics Reagents & IVD Services Business Development, Thermo Fisher Scientific

1.40 | 10.40 The Impact of Digital & Computational Pathology on Biomarker Discovery & Development

  • Jason Hipp Senior Director, Head of Pathology Data Science & Innovation, Translational Medicine, AstraZeneca

2.00 11.00 Improving the Diagnostic Accuracy of the PD-L1 Test with Multiplexing and Image Analysis

  • Matt Humphries Scientific Lead, Tissue Hybridization & Digital Pathology, Precision Medicine Centre of Excellence, Queen's University Belfast

2.20 | 11.20 Science to Medicine: Using Biomarkers & Genetics for Indication Selection & Prioritization in Drug Development

2.40 | 11.40 Live Audience Q+A

  • Jennifer Hamilton Executive Director & Head, Precision Medicine, Regeneron
  • Jason Hipp Senior Director, Head of Pathology Data Science & Innovation, Translational Medicine, AstraZeneca
  • Matt Humphries Scientific Lead, Tissue Hybridization & Digital Pathology, Precision Medicine Centre of Excellence, Queen's University Belfast
  • Colin Hill VP/GM Clinical Diagnostics Reagents & IVD Services Business Development, Thermo Fisher Scientific

3.00 | 12.00 Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay

3.30 | 12.30 Speed Networking

3.45 | 12.45 Immune Profiling to Guide the Development of Next- Generation Immunotherapies

  • Darrell Borger Associate Director, Translational Oncology, ODDU, Takeda

Informing Pipeline Decisions with Early Biomarker Testing & Informatics

4.05 | 1.05 Safety & Pharmacodynamic Biomarker Strategy for Viral Immunotherapy for Cancer

  • Tooba Cheema Director, Translational Medicine & Biomarkers, Oncorus

4.25 | 1.25 Challenges in the Clinical Implementation of Diagnostic Testing for Precision Medicine. Global Perspectives

  • Lourdes Barrera Senior Director, Precision Medicine, Global Precision Medicine Strategy, Oncology Business Unit, Novartis

4.45 | 1.45 Live Audience Q+A

  • Tooba Cheema Director, Translational Medicine & Biomarkers, Oncorus
  • Lourdes Barrera Senior Director, Precision Medicine, Global Precision Medicine Strategy, Oncology Business Unit, Novartis
  • Darrell Borger Associate Director, Translational Oncology, ODDU, Takeda

5.15 | 2.15 Chair’s Closing Remarks & End of Day One